Science and Engineering Ethics

, Volume 10, Issue 1, pp 143–150

The biochemical bases of the placebo effect

Article

DOI: 10.1007/s11948-004-0071-z

Cite this article as:
de la Fuente-Fernández, R. & Stoessl, A.J. SCI ENG ETHICS (2004) 10: 143. doi:10.1007/s11948-004-0071-z

Abstract

A great variety of medical conditions are subject to the placebo effect. Although there is mounting evidence to suggest that the placebo effect is related to the expectation of clinical benefit, little is still known about the biochemical bases underlying placebo responses. Positron emission tomography studies have recently shown that the placebo effect in Parkinson’s disease, pain, and depression is related to the activation of the limbic circuitry. The observation that placebo administration induces the release of dopamine in the ventral striatum of patients with Parkinson’s disease suggests a link between the placebo effect and reward mechanisms. In addition to Parkinson’s disease, the placebo-reward model may also apply to other disorders. However, the relative contribution of the different neurotransmitters and neuropeptides that are known to be involved in modulating the activity of the limbic system may be disease-specific. Thus, while the placebo-induced clinical benefit observed in Parkinson’s disease would mostly reflect the release of dopamine in the dorsal striatum, the activation of opioid and serotonin pathways could be particularly implicated in mediating placebo responses encountered in pain and depression, respectively.

Keywords

placebo effect reward dopamine opioid serotonin 

Copyright information

© Opragen Publications 2003

Authors and Affiliations

  • Raúl de la Fuente-Fernández
    • 1
    • 2
  • A. Jon Stoessl
    • 2
  1. 1.Division of Neurology, Hospital A. Marcide, Estrada San Pedro - Catabois s/nFerrol, A CoruñaSpain
  2. 2.Pacific Parkinson’s Research CentreUniversity of British ColumbiaVancouverCanada

Personalised recommendations